Gilead price target raised to $155 from $152 at Truist

3 weeks ago 11

TipRanks

Thu, April 9, 2026 astatine 7:41 AM CDT 1 min read

Truist expert Gregory Renza raised the firm’s price target connected Gilead (GILD) to $155 from $152 and keeps a Buy standing connected the shares arsenic portion of a broader probe enactment previewing Q1 net successful Biotech. Reactivity to regulatory and argumentation shifts crossed the assemblage continues to ease, and the steadfast besides notes a caller pickup successful woody activity, which has the imaginable to physique momentum done the remainder of the twelvemonth into mid-terms, the expert tells investors successful a probe note. For the company, the steadfast is looking for its absorption commentary connected Yeztugo motorboat strategy and payer entree dynamics successful U.S./EU markets and immoderate anito-cel motorboat mentation updates up of the December 23, 2026 PDUFA, Truist added.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Discover top-performing banal ideas and upgrade to a portfolio of marketplace leaders with Smart Investor Picks

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected GILD:

Disclaimer & DisclosureReport an Issue

Gilead terms people raised to $155 from $152 astatine Truist
Balancing Strategic Oncology Expansion and Execution Risk: Why Gilead’s Tubulis Deal Supports a Hold Rating
Gilead Sciences: Strategic Oncology Expansion and Undervalued Growth Opportunity Driving Buy Rating
Gilead’s Tubulis Acquisition: Building an ADC Oncology Franchise and Enhancing Risk‑Reward for GILD Shares
Leerink says Tubulis woody highlights worth of ADC platforms similar Sutro’s

Read Entire Article